NOD1 antagonists(Nucleotide-binding oligomerization domain-containing protein 1 antagonists), NOD2 antagonists(Nucleotide-binding oligomerization domain-containing protein 2 antagonists)

Therapeutic Areas

Immune System DiseasesDigestive System Disorders

Active Indication

Inflammatory Bowel Diseases

Inactive Indication-

Originator Organization

Infinite- Lille Institute for Translational Research in InflammationStartup

Active Organization

Infinite- Lille Institute for Translational Research in InflammationStartup

Inactive Organization-

Drug Highest PhasePreclinical

First Approval Date-

Regulation-

100 Clinical Results associated with NOD1/NOD2 inhibitors(Infinite- Lille Institute for Translational Research in Inflammation)

100 Translational Medicine associated with NOD1/NOD2 inhibitors(Infinite- Lille Institute for Translational Research in Inflammation)

100 Patents (Medical) associated with NOD1/NOD2 inhibitors(Infinite- Lille Institute for Translational Research in Inflammation)

Literatures (Medical) associated with NOD1/NOD2 inhibitors(Infinite- Lille Institute for Translational Research in Inflammation)

01 Sep 2024·Allergology International

Aspergillus fumigatus extract modulates human eosinophils via NOD2 and oxidative stress

Article

Author: Asano, Koichiro ; Miyata, Jun ; Kawana, Akihiko ; Masaki, Katsunori ; Konno, Ryo ; Fukunaga, Koichi ; Kawashima, Yusuke ; Otsu, Yo ; Sunata, Keeya ; Kimizuka, Yoshifumi ; Matsuyama, Emiko ; Ishikawa, Masaki ; Hasegawa, Yoshinori ; Sasaki, Hisashi ; Ueki, Shigeharu ; Kabata, Hiroki ; Onozato, Ryuta ; Abe, Tomoe

BACKGROUNDAspergillus fumigatus is a pathogenic fungus known to be associated with severe asthma and allergic bronchopulmonary mycosis. However, the precise mechanisms underlying airway inflammation remain unclear. In this study, we investigated the direct modulation of human eosinophils by A. fumigatus and identified the specific mechanism of airway inflammation.METHODSEosinophils isolated from healthy subjects were stimulated with extracts of A. fumigatus. Multi-omics analysis, comprising transcriptomic and proteomic analyses, was performed. The expression of specific factors was evaluated using quantitative real-time polymerase chain reaction and flow cytometry. Mechanistic analyses were performed using NOD2 inhibitor and N-acetyl-l-cysteine (NAC).RESULTSThe A. fumigatus extract changed the expression of adhesion molecules (CD62L and CD11b) and CD69 on the surface of eosinophils, without affecting their viability, via nucleotide-binding oligomerization domain-containing protein 2 (NOD2) but not protease activity. Investigation using kinase inhibitors showed that A. fumigatus extract-induced modulation was partly mediated via p38 mitogen-activated protein kinases. Multi-omics analysis revealed that A. fumigatus-induced gene and protein expression profiles were characterized by the upregulation of oxidative stress-related molecules, including heat shock proteins (HSP90AA1, HSP90AB1, SRXN1, and HMOX1). NOD2 inhibitor and NAC differentially inhibited A. fumigatus-induced inflammatory changes. Additional multi-omics analysis identified that NOD2 signaling induced gene signatures different from those of interleukin (IL)-5 and elicited synergistic change with IL-5.CONCLUSIONSA. fumigatus modulates human eosinophils via NOD2 and oxidative stress-mediated signaling. NOD2 signaling potentiated IL-5-induced activation, suggesting its pathogenic role in type 2 inflammation. NOD2 inhibitors and antioxidants can have therapeutic potential against A. fumigatus-related allergic disorders.

100 Deals associated with NOD1/NOD2 inhibitors(Infinite- Lille Institute for Translational Research in Inflammation)

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Inflammatory Bowel Diseases	Preclinical	FR	Infinite- Lille Institute for Translational Research in InflammationStartup	27 Aug 2024

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

NOD1/NOD2 inhibitors(Infinite- Lille Institute for Translational Research in Inflammation)

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation